No matches
Dermatology

Mechanisms of Disease: Autoimmunity and Role of Type 2 Inflammation in Bullous Pemphigoid (BP)

In this ADVENT symposium at the 2024 EADV meeting, Professor Enno Schmidt discusses the pathophysiology of BP, focusing on autoimmunity and the role of type 2 inflammation.
Enno Schmidt
MD, PhD
Enno Schmidt

Related resources

The Evolving Understanding of Prurigo Nodularis (PN) Has Implications for Patient Management

The Evolving Understanding of Prurigo Nodularis (PN) Has Implications for Patient Management

Infographic
Tools for Clinical Assessment of Prurigo Nodularis

Tools for Clinical Assessment of Prurigo Nodularis

Infographic
Can Emerging Treatments Help Address Individual PN Patient Burden?

Can Emerging Treatments Help Address Individual PN Patient Burden?

expert video
Differences in Manifestations of Type 2 Inflammatory Diseases

Differences in Manifestations of Type 2 Inflammatory Diseases

expert video
Emerging Therapeutic Landscape and Implications for Patient Management in CSU

Emerging Therapeutic Landscape and Implications for Patient Management in CSU

expert video
Exploring Prurigo Nodularis: From Definition to Pathology and Patient Management

Exploring Prurigo Nodularis: From Definition to Pathology and Patient Management

expert video
Mast Cells and the Neuroimmune Axis in CSU

Mast Cells and the Neuroimmune Axis in CSU

expert video
PN is Considered a Unique Clinical Entity Distinct from Other Pruritic Diseases and Psychiatric Conditions

PN is Considered a Unique Clinical Entity Distinct from Other Pruritic Diseases and Psychiatric Conditions

expert video
How Should We Define and Classify Prurigo Nodularis?

How Should We Define and Classify Prurigo Nodularis?

expert video
UCARE 2023: Potential Role of Type 2 Cytokines in CSU Pathogenesis

UCARE 2023: Potential Role of Type 2 Cytokines in CSU Pathogenesis

expert video
What Drives PN Disease? Exploring the Complexity of PN Pathophysiology

What Drives PN Disease? Exploring the Complexity of PN Pathophysiology

expert video
Skin Barrier Dysfunction and Type 2 Inflammation in Atopic Dermatitis

Skin Barrier Dysfunction and Type 2 Inflammation in Atopic Dermatitis

videoanimation
What is Early Intervention in AD?

What is Early Intervention in AD?

expert video
Disease Modification in AD

Disease Modification in AD

expert video
Systemic Inflammation in AD – Beyond the Skin

Systemic Inflammation in AD – Beyond the Skin

expert video
Dysbiosis, Skin Infections, and Itch

Dysbiosis, Skin Infections, and Itch

expert video
Skin Barrier Dysfunction in AD

Skin Barrier Dysfunction in AD

expert video
Early Intervention and the Potential for Disease Modification in Children With AD

Early Intervention and the Potential for Disease Modification in Children With AD

expert video
Emerging Data on Advanced Systemic Treatments for Children With AD

Emerging Data on Advanced Systemic Treatments for Children With AD

expert video
Within and Beyond the Skin: New Perspectives on the Role of Type 2 Inflammation in AD

Within and Beyond the Skin: New Perspectives on the Role of Type 2 Inflammation in AD

expert video
The Role of Type 2 Inflammation in Skin Barrier Dysfunction in Atopic Dermatitis

The Role of Type 2 Inflammation in Skin Barrier Dysfunction in Atopic Dermatitis

expert video
Skin Dysbiosis in AD

Skin Dysbiosis in AD

expert video
Navigating Recent Scientific Advances in Atopic Dermatitis: Skin Barrier Dysfunction, Dysbiosis, and Itch

Navigating Recent Scientific Advances in Atopic Dermatitis: Skin Barrier Dysfunction, Dysbiosis, and Itch

expert video
The Impact of Skin Dysbiosis on Atopic Dermatitis

The Impact of Skin Dysbiosis on Atopic Dermatitis

expert video
The Association Between Epidermal Barrier Dysfunction and S. aureus Colonization in Atopic Dermatitis

The Association Between Epidermal Barrier Dysfunction and S. aureus Colonization in Atopic Dermatitis

expert video
Role of Type 2 Inflammation in Skin Barrier Dysfunction in AD

Role of Type 2 Inflammation in Skin Barrier Dysfunction in AD

expert video
The Impact of Type 2 Inflammation on the Neuroimmune Axis in AD

The Impact of Type 2 Inflammation on the Neuroimmune Axis in AD

expert video
Unmet Needs for Bullous Pemphigoid (BP): Limitations of Diagnosis and Conventional Therapies

Unmet Needs for Bullous Pemphigoid (BP): Limitations of Diagnosis and Conventional Therapies

expert video
Atopic Dermatitis in Children: Can Early Therapeutic Intervention Shape Disease Course?

Atopic Dermatitis in Children: Can Early Therapeutic Intervention Shape Disease Course?

expert video
New Horizons in Children With Atopic Dermatitis: Emerging Evidence in Disease Management

New Horizons in Children With Atopic Dermatitis: Emerging Evidence in Disease Management

expert video
New Perspectives in Understanding Pathophysiology of Atopic Dermatitis in Children

New Perspectives in Understanding Pathophysiology of Atopic Dermatitis in Children

expert video
Current Treatment Landscape and Emerging Therapies

Current Treatment Landscape and Emerging Therapies

expert video
Skin Barrier Dysfunction and Increased Risk of Allergen Sensitization May Impact Atopic March in Atopic Dermatitis (AD)

Skin Barrier Dysfunction and Increased Risk of Allergen Sensitization May Impact Atopic March in Atopic Dermatitis (AD)

Infographic
The Potential Long-term Consequences in AD in Children: Cardiovascular Risk, Bone Health, and Mental Health

The Potential Long-term Consequences in AD in Children: Cardiovascular Risk, Bone Health, and Mental Health

expert video
The Relationship Between Skin Barrier Dysfunction and Increased Risk of Allergen Sensitization in AD

The Relationship Between Skin Barrier Dysfunction and Increased Risk of Allergen Sensitization in AD

expert video
How Can We Explore the Concept of Disease Modification in Children With AD?

How Can We Explore the Concept of Disease Modification in Children With AD?

expert video
Overview of Type 2 Inflammation in the Presentations of AD, PN, and CSU

Overview of Type 2 Inflammation in the Presentations of AD, PN, and CSU

expert video
Differences in Itch in AD, PN, and CSU

Differences in Itch in AD, PN, and CSU

expert video
Contribution of Type 2 Cytokines to Inflammation and Itch in AD, PN, and CSU 

Contribution of Type 2 Cytokines to Inflammation and Itch in AD, PN, and CSU 

expert video
Itch in AD, PN and CSU: Role of Type 2 Inflammation

Itch in AD, PN and CSU: Role of Type 2 Inflammation

expert video
Clinical Presentations in AD, PN, and CSU: Role of Type 2 Inflammation

Clinical Presentations in AD, PN, and CSU: Role of Type 2 Inflammation

expert video
Shared and Unique Characteristics of AD, PN, and CSU

Shared and Unique Characteristics of AD, PN, and CSU

expert video
Emerging Understanding of Chronic Itchy Skin Diseases – Shared and Unique Drivers in AD, PN, and CSU

Emerging Understanding of Chronic Itchy Skin Diseases – Shared and Unique Drivers in AD, PN, and CSU

Infographic
Emerging Understanding of Chronic Itchy Skin Diseases: Shared and Unique Drivers in AD, PN, and CSU

Emerging Understanding of Chronic Itchy Skin Diseases: Shared and Unique Drivers in AD, PN, and CSU

expert video
New Perspectives on Disease Modification in Atopic Dermatitis - Panel Discussion

New Perspectives on Disease Modification in Atopic Dermatitis - Panel Discussion

expert video
Itch: The Common Thread in Dermatological Type 2 Inflammation (AD, PN, and CSU)​ - Panel Discussion

Itch: The Common Thread in Dermatological Type 2 Inflammation (AD, PN, and CSU)​ - Panel Discussion

expert video
Itch: Neuroimmune Axis in Chronic Pruritic Skin Diseases

Itch: Neuroimmune Axis in Chronic Pruritic Skin Diseases

expert video
Neuroimmune Axis in Atopic Dermatitis

Neuroimmune Axis in Atopic Dermatitis

expert video
New Perspectives on Disease Modification in Atopic Dermatitis

New Perspectives on Disease Modification in Atopic Dermatitis

expert video
Exploring The Concept of Disease Modification in Atopic Dermatitis

Exploring The Concept of Disease Modification in Atopic Dermatitis

expert video

Learning objectives

  • Highlight current understanding of BP pathophysiology and the critical role of autoimmunity and type 2 inflammation in both clinical signs and itch

Description

Join Professor Enno Schmidt as he discusses the pathophysiology of bullous pemphigoid (BP), focusing on autoimmunity and the role of type 2 inflammation, including a mechanism of disease video

Tags
type 2 inflammationmechanism of disease
MAT-GLB-2406784 - 1.0 - 10/2024

About this expert

Dermatology

Enno Schmidt

MD, PhD

Director, Lübeck Institute of Experimental Dermatology Senior Consultant, Department of Dermatology University of Lübeck, Lübeck, Germany

See author’s profile
Enno Schmidt

ADVENT is a global medical education non-promotional program by Sanofi and Regeneron. This website is intended only for duly authenticated healthcare professionals in Algeria, Argentina, Australia, Austria, Bahrain, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Costa Rica, Croatia, Czech Republic, Denmark, Dominican Republic, Ecuador, Egypt, Estonia, Finland, France, Germany, Greece, Guatemala, Hong Kong, Hungary, Iceland, India, Israel, Italy, Japan, Kuwait, Latvia, Lebanon, Lithuania, Macau, Malaysia, Norway, Oman, Panama, Peru, Poland, Portugal, Qatar, Romania, Saudi Arabia, Singapore, Slovenia, South Africa, South Korea, Spain, Sudan, Sweden, Switzerland, Taiwan, Thailand, The Netherlands, Turkey, United Arab Emirates, or the United States of America.

For healthcare professionals in Algeria: Please read the additional Terms of Use.

Sanofi | Regeneron Logo

© 2025 Sanofi and Regeneron Pharmaceuticals, Inc.

All rights reserved.
MAT-GLB-2302957 v3.0 11/2023

All Rights Reserved.

Sanofi and Regeneron are global leaders in pharmaceutical development, each with a long history of supporting frontline physicians to improve human health and reduce the burden of disease. Driven by the same commitment to patients and their families, Sanofi and Regeneron have partnered to take on type 2 inflammation and the range of chronic conditions in which excessive inflammation plays a role.

Country/region: ChinaChange country/region